CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight

The CDK4/6 inhibitors market is expected to grow significantly in the coming years. This is mainly due to the increasing incidence of HR+/HER2 breast cancer, the type for which CDK4/6 inhibitors are majorly prescribed. CDK4/6 inhibitors are now an established class, with all three…